Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FKBP5 and resistant attachment predict cortisol reactivity in infants: gene-environment interaction.

Psychoneuroendocrinology·2010

Same author

Common genetic determinants of vitamin D insufficiency: a genome-wide association study.

Lancet (London, England)·2010

Same author

Heart failure and incident late-life depression.

Journal of the American Geriatrics Society·2010

Same author

Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study.

The Journal of clinical endocrinology and metabolism·2010

Same author

Predicting survival and morbidity-free survival to very old age.

Age (Dordrecht, Netherlands)·2010

Same author

Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index.

Annals of the rheumatic diseases·2010

Search research articles

Related Experiment Videos

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin

Matthijs L Becker¹, Loes E Visser, Ron H N van Schaik

¹Department of Epidemiology, Erasmus MC, 3000 CA Rotterdam, the Netherlands.

Pharmacoepidemiology and Drug Safety

|October 6, 2009

Summary

The CYP3A4*1B G allele may lower the risk of statin dose reduction or drug switching, especially in women. This finding is linked to statin metabolism and transport genetic variations.

Related Experiment Videos

Area of Science:

Pharmacogenomics
Cardiovascular pharmacology

Background:

Simvastatin and atorvastatin are statins metabolized by CYP3A4 and transported by ABCB1.
Genetic variations in CYP3A4 and ABCB1 may influence statin therapy outcomes.
Dose reduction or drug switching can indicate adverse drug reactions or excessive cholesterol reduction.

Purpose of the Study:

To investigate the association between CYP3A4*1B and ABCB1 gene polymorphisms and statin dose adjustments.
To determine if genetic variations impact the likelihood of switching cholesterol-lowering drugs during simvastatin or atorvastatin therapy.

Main Methods:

A cohort of 1239 simvastatin and atorvastatin users from the Rotterdam Study was analyzed.
Cox proportional hazards models were used to assess the time to dose decrease or drug switch.
Polymorphisms studied included CYP3A4*1B and ABCB1 (C1236T, G2677A/T, C3435T).

Main Results:

The CYP3A4*1B variant G allele was associated with a reduced risk of dose reduction or drug switch (HR 0.46).
No significant associations were found for ABCB1 gene polymorphisms.
The protective effect of CYP3A4*1B G allele was more pronounced in women and in individuals with the ABCB1 3435T variant allele.

Conclusions:

The CYP3A4*1B G allele is linked to a lower risk of adverse statin effects, suggesting altered plasma levels.
This association is particularly relevant for women and individuals carrying the ABCB1 3435T variant.
Genetic factors play a role in individual responses to simvastatin and atorvastatin therapy.